White Blood Cell Growth Factors Guideline Update

About this episode

Dr. Bishal Gyawali and Dr. Tessa Cigler discuss the updated ASCO guidelines on hematopoietic colony-stimulating factors in cancer patients.

Dr. Bishal Gyawali and Dr. Tessa Cigler share the new, comprehensive, evidence-based update of the ASCO guideline on the use of hematopoietic colony-stimulating factors in patients with cancer. They discuss recommendations on primary prophylaxis, secondary prophylaxis, and treatment of febrile neutropenia along with stem cell mobilization, efficacy, safety, duration, dosing, and administration of CSFs – including biosimilars. They highlight where it is appropriate to use a CSF, and importantly, when not to use a CSF. They touch on the significance of individual patient considerations and cost implications, and future work to refine the risk factors for the development of complications of febrile neutropenia. Read the full guideline, " White Blood Cell Growth Factors: ASCO Guideline Update " at www.asco.org/supportive-care-guidelines TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/supportive-care-guidelines . Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-25-02938 Brittany Harvey: Hello and welcome to the ASCO…

People in this episode

Host: Brittany Harvey

Guests: Dr. Bishal Gyawali, Dr. Tessa Cigler

Topics covered

• hematopoietic colony-stimulating factors
• cancer treatment
• febrile neutropenia
• guideline update
• patient considerations
• cost implications

Keywords

• CSFs
• primary prophylaxis
• secondary prophylaxis
• stem cell mobilization
• biosimilars
• safety
• efficacy
• dosing
• administration

Mentioned in this episode

Organizations: American Society of Clinical Oncology

Books & works: White Blood Cell Growth Factors: ASCO Guideline Update

More episodes of ASCO Guidelines

• Systemic Treatment of Thyroid Cancer Guideline · April 1, 2026 · 23 min
• Patient-Clinician Communication Guideline Update · March 10, 2026 · 31 min
• Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer Guideline Update · February 26, 2026 · 29 min
• Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2026.3.0 Part 2 · February 3, 2026 · 20 min
• Therapy for Stage IV NSCLC Without Driver Alterations: ASCO Living Guideline Update 2026.3.0 Part 1 · February 3, 2026 · 18 min
• Systemic Therapy in Patients With mCRPC: ASCO Living Guideline 2026.1 · January 20, 2026 · 14 min